Reunion Neuroscience initiated with a Buy at EF Hutton

EF Hutton analyst Elemer Piros initiated coverage of Reunion Neuroscience with a Buy rating and $11 price target. Reunion, which has begun clinical testing of a novel psychedelic drug that "could become best-in-class" for the treatment of depression, will first target postpartum depression, which Piros says is "to date almost completely unaddressed by other drugs."